VBIV - Valneva VBI Vaccines in pact to launch Hep B vaccine in Europe

• French biotech Valneva SE ( VALN ) and U.S.-based VBI Vaccines ( NASDAQ: VBIV ) announced a partnership on Wednesday to jointly market and distribute the PreHevbri Hepatitis B vaccine in select European countries starting from early next year.
• The companies said that PreHevbri, developed by VBIV, is the only 3-antigen hepatitis B vaccine approved in Europe.
• Per the terms, VALN will promote and distribute PreHevbri in certain European countries, which will initially include the U.K., Sweden, Norway, Denmark, Finland, Belgium, and the Netherlands.
• The companies expect to make PreHevbri available in these countries in early 2023.
• In April, the European regulators greenlighted PreHevbri for active immunization of adults against infection caused by all known subtypes of hepatitis B virus. The U.K. authorization followed weeks later.

For further details see: